The effects of 5 mg of diazepam intravenously were assessed in 23 patients with liver disease, 10 of whom had clinical evidence either in the past or at the time of study of' hepatic encephalopathy. Transient drowsiness occurred in all patients, but prolonged deterioration in conscious level was not observed. Serial electroencephalographic recordings showed the development of activity at faster frequencies, similar to that found in normal subiects, a change which is different from that usually observed in cirrhotic patients after administration of chlorpromazine and morphine when slow-wave activity is increased.
Introduction
Patients with liver disease are known to be unusually sensitive to certain sedatives and analgesics, particularly paraldehyde and morphine, and hepatic coma may follow their administration (Laidlaw et al., 1961) . Nevertheless, sedation may sometimes be necessary in these patients, particularly during the early stages of hepatic encephalopathy when they are often noisy and restless. Sedation may also be required for the alcoholic with delirium tremens who so often has underlying liver disease. Chlorpromazine has been recommended, but Read et al. (1969) showed that this could be followed by a prolonged period of drowsiness accompanied by slowing of the electroencephalogram (E.E.G.). Though phenobarbitone can be useful its effects tend to be cumulative, particularly in renal failure which may complicate severe liver disease. The sedative diazepam (Valium), which has proved safe in a variety of other clinical situations, seemed to us to have a number of potential advantages in the patient with liver disease, and in this paper we report a clinical and electroencephalographic assessment of its effects.
Patients and Methods
The clinical diagnosis of the 23 patients examined, confirmed by needle biopsy in each case, were as follows: alcoholic cirrhosis (6), cryptogenic cirrhosis (5), active chronic hepatitis with cirrhosis (4), primary biliary cirrhosis (1), viral hepatitis (2), henatic neoplasm (3), chronic Budd-Chiari syndrome (1), and obstructive jaundice (1). In 10 of the 16 cirrhotic patients there had been a previous episode of hepatic precoma and three of these were in grade I hepatic encephalopathy (Trey et al., 1966) Aitken (1966) , in which a mean dominant frequency was calculated with only those freauencies of greater than average abundance, was also used. The latter, since it allows for a skew distribution of frequencies, has been termed in this paper "skew mean dominant frequency." As it is usually determined from only three to five frequencies, it is generally less affected than is the mean dominant frequency by slow and fast frequency artefacts in the recording. The slow-wave index, a measure of relative and absolute activity at 2-3 c/s, was also calculated (Laidlaw and Aitken, 1966 , 1970) . Study of the disappearance curve of diazepam from the blood after oral and parenteral administration (Schwartz et al., 1965; de Silva et al., 1966) indicates rapid and extensive uptake by tissues with an overall drug half-life of two to three days, and if 30 mg orally is given daily there is a progressive increase in plasma diazesam levels (de Silva et al., 1966) . In keeping with this are the effects of diazepam on the E.E.G. which may take some days to develop fully during continued administration and may persist for some days after discontinuation of the drug (Towler et al.. 1962; Metcalfe and Whitley, 1964) . The main change in the E.E.G. observed in normal subjects is the aomearance of low to moderate voltage fast activity first in the frontal areas and spreading posteriorly with a reduction in amplitude of normal alpha rhythm. Though the major site of metabolic breakdown of diazepam by dernethylation, hydroxylation, and conjugation is in the liver, the response of our patients with liver disease does not differ from that reported for normal subjects (Healy et al., 1970) . In particular drowsiness was not prolonged or exaggerated even in those with hepatic encephalonathy. A reduction in E.E.G. dominant freauency and an increase in slow-wave activity give some index of the severity of liver disease (Laidlaw and Read, 1963) , and our patients with henatic encephalopathy either in the nast or at the time of study showed the most pronounced E.E.G. changes. Even in these patients, however, there was no tendency to develop increased slow activity in the E.E.G. as has been described after morphine or chlorpromazine.
The results of present studies show that a single injection of 5 mg of diazepam is safe when assessed both clinically and by serial E.E.G. recordings in a group of patients with relatively well compensated chronic liver disease. We have also had some clinical experience of it in patients with fulminant hepatic failure. It can be of value in controlling the epileptic convulsions that these patients so often have. A dose of 5 mg intravenously given slowly over 10 minutes is sufficient on most occasions, but this dosage may be repeated after 30 minutes and then up to four-hourly. With such a regimen we have sometimes observed depression of respiration-a hazard to which these patients are particularly prone-and careful monitoring is essential.
Introduction
Metolazone is a quinazolinone diuretic, chemically related to quinethazone. Its action resembles that of thiazides, though animal experiments indicate that it is more potent and less kaliuretic. Diuresis begins within two hours and persists for 24 hours in normal subjects. Dose-response studies in normal subjects show that a maximum diuretic activity is observed on raising the dose to 10 mg. The purpose of this study was to determine the efficacy of metolazone in controlling ascites due to liver disease and to assess the incidence of complications, particularly electrolyte disturbance.
Patients and Methods
Twenty patients with chronic liver disease and persistent ascites were studied (Table I) . They were put to bed, weighed daily, and given a 22-mEq sodium diet. Fluid intake was restricted to 1,000 ml a day. Protein intake was 60-70 g except during episodes of encephalopathy. Fluid intake and output and 24-hour urine sodium, potassium, and chloride were measured. Blood urea, electrolytes liver function tests,
